A phase 1b study of durvalumab (MEDI4736) alone or in combination with pomalidomide (POM) with or without low dose-dexamethasone (LoDEX) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).
2016
TPS8072Background: Multiple myeloma (MM) plasma cells express programmed cell death ligand 1 (PD-L1). In preclinical studies, monoclonal antibodies (mAbs) directed against PD-L1 demonstrated antimy...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
2
Citations
NaN
KQI